The WHO backed GLP-1 therapy for obesity, then did the arithmetic on supply

The World Health Organization issued its first guideline on GLP-1 therapies and conditionally recommends them for adults living with obesity from a body mass index of 30 upward. Beside it sits the number that reorders the conversation: even in the highest projected scenario, production could cover about 100 million people, under 10 percent of those living with obesity today.

Money is the real gate, and the guideline names the cost barrier without flinching. What governments can do fills a list: negotiate prices with the manufacturer, open the marketplace to competition, buy in blocs, back local production, use voluntary or compulsory licences. Generic versions arriving next year could open a door in some countries.

Both recommendations are conditional, which means the desirable consequences do not clearly outweigh the undesirable ones. What pulled the panel's confidence down was the current high price, health systems that are not ready, equity implications, and thin evidence on stopping and restarting; the trials behind it ran 6 to 40 months.

For a household none of this changes the counter price by itself. It is guidance to governments and clinicians rather than a coverage decision, so what a person pays each month still depends on which country they live in.

Read the full story at Medscape en Español ↗

Retatrutide is investigational and is not FDA-approved. Other medicines referenced here are covered as third-party news for educational awareness only. Catalyst does not present this information as medical advice, treatment guidance, or a claim of safety, efficacy, or approval.